In 2016, thanks to a collaborative fundraising campaign, we raised the funds necessary to acquire an instrument needed to “manufacture” CAR-Ts. A Prodigy®, a machine needed to inoculate T-lymphocytes with a virus in an absolutely safe and watertight manner. And make the personalised cells grow in enough quantity to be administered to the patient.
But the technical explanation is complex. That’s why we call it the factory of unstoppable cells. In 2018, we set ourselves the goal of raising one million euros so that the first CAR-T cell clinical trial could be undertaken in Europe for patients with Hodgkin’s lymphoma and T-type Hodgkin’s lymphomas in relapse. And we achieved it!